Aardvark Therapeutics, Inc., Announces Poster Presentations at the 2020 Obesity Week Conference

San Diego, Calif., November 2, 2020 – Aardvark Therapeutics, Inc., today announced that it will present two posters at the 2020 Obesity Week Conference which is being held in virtual format this year due to COVID-19 from November 2 -6, 2020.

Presentation details are as follows:

Poster Title: Efficacy of ARD-101, a Bitter Taste Receptor (TAS2R) Agonist, in Rodent Models of Obesity
Presenter: Andreas Niethammer, MD PhD
Track: Track 1: Metabolism and Integrative Physiology
Category: HPA Axis
Poster #: 170

Poster Title: Microbiome Changes in Mice After Treatment with ARD-101,a Bitter Taste Receptor (TAS2R) Agonist
Presenter: Andreas Niethammer, MD PhD
Track: Track 1: Metabolism and Integrative Physiology
Category: NAFLD
Poster #: 282

About Aardvark Therapeutics, Inc.:
Aardvark Therapeutics is a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for inflammation, metabolic diseases, and other indications.

Forward Looking Statements
This press release contains, in addition to historical information, statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding our plans, expectations and goals regarding the clinical trial, our future development plans, and the potential benefits of ARD-101 in multiple clinical indication.  Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trial are subject to factors beyond our control. Our clinical trial may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. In regard to our clinical trial, we may have difficulty in enrolling candidates for testing, which would impact our estimates regarding timing, and we may not be able to achieve the desired results. Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including ARD-101, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

SOURCE Aardvark Therapeutics, Inc.

[email protected]